Home›Clinical trials›Texas

GLP-1 clinical trials in Texas: 55 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

55 GLP-1 clinical trials are recruiting at 266 sites in 55 cities across Texas. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Texas

  1. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    8 sites in Texas
    • Precision Comprehensive Clinical Research Solutions - Colleyville, Colleyville. 9722998399
    • AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Fort Worth, Fort Worth. 817-789-6770
    • Accurate Clinical Research, Inc, Houston. 281-481-8557
    • Research Physicians Network, LLC, Houston. 281-944-3610
    • AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving, Irving
    • Biopharma Informatic, LLC, Katy. (281) 944-3610
    • Advanced Rheumatology of Houston - Woodlands, The Woodlands. 936-681-4882
    • DM Clinical Research - TRA, Tomball. 281-517-0550

  2. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    6 sites in Texas

  3. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in Texas

    • Premier Internal Medicine Associates of Houston, Katy. 281-398-8044
    • North Dallas Research Associates, McKinney. 972-529-6939

  4. Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

    Phase 4. Run by Marzieh Salehi. Registry number NCT06706284.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with spinal cord injuries lower blood sugar.

    Who can join. Adults 18 to 70, have spinal cord injuries, BMI 22+.

    2 sites in Texas

    • University Health - Texas Diabetic Institute, San Antonio
    • University of Texas Health Science Center at San Antonio, San Antonio

  5. Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

    Phase 4. Run by The University of Texas Health Science Center, Houston. Registry number NCT05119179.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with prediabetes lower blood sugar.

    Who can join. Adults 18+, have prediabetes, BMI 30+.

    1 site in Texas

    • UTHealth Clinical Research Unit (CRU) at UT Brownsville, Brownsville. 956-755-0695

  6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    38 sites in Texas

  7. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    29 sites in Texas
    • American Research Corporation, Austin. 210-253-3426
    • IMA Clinical Research Austin, Austin. 512-649-0082
    • Pinnacle Clinical Research, Austin. 512-384-1460 x3001
    • Bellaire Clinical Research, Bellaire
    • Headlands Horizons, LLC dba Headlands Research-Brownsville, Brownsville
    • South Texas Research Institute - Brownsville, Brownsville. 956-468-3360
    • Soma Clinical Trials, Denison. 469-819-0228
    • Epic Medical Research - DeSoto, DeSoto. 197-277-7695
    • South Texas Research Institute, Edinburg. 956-468-3360
    • Dallas Research Institute, Farmers Branch. 214-347-7577
    • Care United Research, LLC, Forney. 972-564-0044
    • GI Alliance - Fort Worth, Fort Worth. 817-612-5575
    • Biopharma Informatic, LLC, Houston. 281-944-3610
    • Care Access - Houston, Houston. 877-791-0656
    • Houston Research Institute, Houston. 281-809-3234
    • HRI- Medical Center, Houston
    • Research Physicians Network, LLC, Houston. 281-944-3610
    • Biopharma Informatic, LLC, McAllen. 281-944-3610
    • DHR Health Institute for Research and Development (Administrative Office & Laboratory), McAllen. 956-362-2390
    • Southern Endocrinology Associates, Mesquite. 214-693-0904
    • HRI Pasadena, Pasadena. 832-847-1727
    • American Research Corporation at Texas Liver Institute, San Antonio. 210-253-3426
    • Clinical Trials of Texas, LLC dba Flourish Research, San Antonio. 210-949-0122
    • IMA Clinical Research San Antonio, San Antonio. 210-692-7157
    • Consano Clinical Research, LLC, Shavano Park. 210-545-4900
    • GI Alliance - Southlake, Southlake. 940-367-2316
    • Houston Research Institute (HRI) - Sugar Land, Sugar Land
    • Texas Valley Clinical Research, Weslaco. 956-431-8090
    • Medrasa Clinical Research, Wylie. 469-449-3645

  8. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    27 sites in Texas

  9. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    19 sites in Texas
    • Amarillo Med Spec LLP, Amarillo
    • Texas Diab & Endo, P.A., Austin
    • Velocity Clinical Research Austin, Austin
    • North Texas Endocrine Center, Dallas
    • Velocity Clin Res, Dallas, Dallas
    • Cedar Health Research, Euless
    • JCCT- Juno NW Houston, Houston
    • The Endocrine Center, Houston
    • Medical Colleagues-Texas LLP, Katy
    • Sante Clinical Research, Kerrville
    • Radiance Clinical Research, Lampasas
    • Aeres Clinical Research, Laredo
    • DCOL Ctr for Clin Res, Longview
    • RGV Endocrine Center, McAllen
    • AES San Antonio, San Antonio
    • Northeast Clinical Research of San Antonio, San Antonio
    • Quality Research Inc, San Antonio
    • Consano Clinical Research, LLC, Shavano Park
    • Mt Olympus Medical Research, LLC, Sugar Land

  10. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    13 sites in Texas

  11. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

    Phase 3. Run by Amgen. Registry number NCT07575399.

    A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

    8 sites in Texas
    • Epic Medical Research - DeSoto, DeSoto
    • South Texas Research Institute, Edinburg
    • Biopharma Informatic, LLC, Houston
    • Research Physicians Network, LLC, Houston
    • Texas Institute of Cardiology, McKinney
    • North Hills Medical Research, North Richland Hills
    • VIP Trials, San Antonio
    • Northwest Houston Heart Center, Tomball

  12. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    6 sites in Texas
    • Dell Children's Medical Center - PIN, Austin
    • Driscoll Children's Hospital, Corpus Christi
    • Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston. 281-517-0550
    • La Providence Pediatrics Clinic - Chemidox Clinical Trials, Houston. 833-324-3643
    • McGovern Medical School, Houston
    • Martin Diagnostic Clinic, Tomball. 281-517-0550

  13. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    6 sites in Texas
    • DM Clinical, Houston
    • DM Clinical, San Antonio
    • Pinnacle Clinical Research, San Antonio
    • The Texas Liver Institute, San Antonio
    • Consano Clin Res-Shavano Park, Shavano Park
    • Texas Valley Clinical Research, Weslaco

  14. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    6 sites in Texas
    • Research Site, Dallas
    • Research Site, Houston
    • Research Site, Katy
    • Research Site, San Antonio
    • Research Site, Sugar Land
    • Research Site, Weslaco

  15. A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06439277.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    5 sites in Texas
    • Driscoll Children's Hospital, Corpus Christi
    • Epic Medical Research - DeSoto, DeSoto
    • Valley Institute of Research - Fort Worth, Fort Worth
    • Consano Clinical Research, LLC, Shavano Park
    • Texas Valley Clinical Research, Weslaco

  16. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    5 sites in Texas

  17. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

    Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

    4 sites in Texas

    • Biopharma Informatic, LLC, Houston. 281-944-3610
    • Research Physicians Network, LLC, Houston. 832-847-1724
    • Sherman Clinical Research, Sherman. 903-771-4093
    • NextStage Clinical Research - Waco, Waco

  18. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672939.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 12 to 17, have obesity.

    3 sites in Texas

    • Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston
    • La Providence Pediatrics Clinic - Chemidox Clinical Trials, Houston
    • Martin Diagnostic Clinic, Tomball

  19. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    3 sites in Texas

  20. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    3 sites in Texas

The other 35 studies recruiting in Texas

  1. Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

    Phase 3. Run by The University of Texas Health Science Center at San Antonio. Registry number NCT06246799.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    2 sites in Texas

    • University Health System Texas Diabetic Institute, San Antonio. 210-567-2391
    • UT Health Science Center, San Antonio

  2. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

    Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

    2 sites in Texas

    • Innovative Medical Research of Texas, Houston
    • Next Level Urgent Care, Houston. 832-460-3311

  3. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    2 sites in Texas

    • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas. 214-857-0125
    • Michael E. DeBakey VA Medical Center, Houston, TX, Houston. 713-798-7658

  4. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in Texas

    • Kailera Clinical Site, Brownsville
    • Kailera Clinical Site, San Antonio

  5. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Run by Vanda Pharmaceuticals. Registry number NCT07446439.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    2 sites in Texas

  6. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Texas

    • Cedar Health Research, Dallas

  7. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    7 sites in Texas
    • IMA Clinical Research Austin, Austin. 512-649-0082
    • FutureSearch Trials of Dallas, Dallas. 214-369-2600
    • Velocity Clinical Research, Dallas, Dallas
    • PlanIt Research, PLLC, Houston. 713-973-3415
    • Endeavor Clinical Trials, San Antonio. 518-428-6859
    • Tekton Research - Fredericksburg Road, San Antonio
    • Texas Valley Clinical Research, Weslaco. 956-431-8090

  8. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    6 sites in Texas
    • IMA Clinical Research, Austin
    • Private Practice - Dr. Laila A. Hassan, Houston
    • Radiance Clinical Research, Lampasas
    • Quality Research Inc, San Antonio
    • Tekton Research Inc, San Antonio
    • Consano Clin Res-Shavano Park, Shavano Park

  9. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    5 sites in Texas

  10. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Run by Biomea Fusion Inc. Registry number NCT07502508.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    5 sites in Texas
    • Elligo Health Research, Inc., Austin
    • Zenos Clinical Research, Dallas
    • Synergy Group Medical, Houston
    • Epic Clinical Research, Lewisville
    • Diabetes & Glandular Disease Clinic, P.A., San Antonio

  11. A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT06717698.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0519-0130, can help people with chronic kidney disease protect their kidneys.

    Who can join. Adults 18+, have chronic kidney disease, BMI 27+.

    3 sites in Texas

    • Davita Clinical Research, El Paso
    • Clinical Advancement Center, San Antonio
    • Tekton Research, San Antonio

  12. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07415954.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    3 sites in Texas

    • University of Texas Southwestern Medical Center, Dallas
    • JCCT- Juno NW Houston, Houston
    • Consano Clinical Research, LLC, Shavano Park

  13. A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

    Phase 2. Run by Regeneron Pharmaceuticals. Registry number NCT07527910.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD), BMI 30+.

    3 sites in Texas

    • American Research Corporation, Austin
    • Advanced Medical Trials, Georgetown
    • American Research Corporation at The Texas Liver Institute, San Antonio

  14. Semaglutide for Post-Smoking Cessation Weight Management

    Phase 2. Run by The University of Texas Health Science Center, Houston. Registry number NCT06173778.

    A study testing whether a GLP-1 medicine, semaglutide, can help people trying to quit smoking lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    2 sites in Texas

    • The University of Texas at Austin, Austin. 573-825-2620
    • The University of Texas Health Science Center at Houston, Houston. 713-486-2737

  15. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in Texas

    • PlanIt Research, PLLC, Houston
    • Pinnacle Clinical Research, San Antonio

  16. Tirzepatide Weight Loss for MRD+ Early Breast Cancer

    Phase 2. Run by Baylor Research Institute. Registry number NCT06517212.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, may help during breast cancer treatment.

    Who can join. Adults 18+, have breast cancer, BMI 27+.

    1 site in Texas

    • Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas. 214-820-5424

  17. Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

    Phase 2. Run by The University of Texas Health Science Center at San Antonio. Registry number NCT06811324.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.

    Who can join. Adults 50+, have obesity, BMI 30+.

    1 site in Texas

    • University of Texas Health Science Center at San Antonio, San Antonio

  18. Tirzepatide to Slow Biological Aging

    Phase 2. Run by The University of Texas Medical Branch, Galveston. Registry number NCT07220473.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, affects healthy aging.

    Who can join. Adults 55 to 70, have aging, BMI 27+.

    1 site in Texas

  19. Tailored Exercise Training Study Among Adults With HFpEF

    Phase 2. Run by University of Texas Southwestern Medical Center. Registry number NCT07223242.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with heart failure with preserved ejection fraction.

    Who can join. Adults 18+, have heart failure with preserved ejection fraction.

    1 site in Texas

    • University of Texas Southwestern Medical Center, Dallas. 214-645-9868

  20. Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

    Phase 2. Run by The University of Texas Health Science Center, Houston. Registry number NCT07227948.

    A study of a GLP-1 medicine, semaglutide, in people with cocaine use disorder.

    Who can join. Adults 18+, have cocaine use disorder, BMI 25+.

    1 site in Texas

    • The University of Texas Health Science Center at Houston, Houston. 713-486-2737

  21. Incretin Microdosing for Cardiometabolic Health in People With HIV

    Phase 2. Run by The University of Texas Health Science Center, Houston. Registry number NCT07325500.

    A study of a GLP-1 medicine, semaglutide.

    Who can join. Adults 18+, have weight gain, BMI 27+.

    1 site in Texas

    • The University of Texas Health Science Center at Houston, Houston. 713-500-6767

  22. PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm

    Phase 2. Run by Veru Inc. Registry number NCT07446998.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with mobility disability lose weight.

    Who can join. Adults 65+, have obesity or are overweight, BMI 35+.

    1 site in Texas

  23. Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

    Phase 1. Run by The University of Texas Health Science Center at San Antonio. Registry number NCT00992901.

    A study of a study medicine, Exendin-(9-39), in people with hypoglycemia.

    Who can join. Adults 18 to 65, have hypoglycemia.

    2 sites in Texas

    • South Texas Veterans Health Care System, San Antonio. 210-567-6691
    • Texas Diabetes Institute - University Health System, San Antonio. 210-450-8696

  24. Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

    Phase 1. Run by The University of Texas Health Science Center at San Antonio. Registry number NCT01803451.

    A study of a study medicine, exendin-(9-39).

    2 sites in Texas

    • South Texas Veterans Health Care System, San Antonio. 210-567-6691
    • Texas Diabetes Institute - University Health System, San Antonio. 210-450-8696

  25. The Effects of Bariatric Surgeries on Glucose Metabolism

    Phase 1. Run by The University of Texas Health Science Center at San Antonio. Registry number NCT02823665.

    A study of a study medicine, Exendin-(9-39).

    2 sites in Texas

    • South Texas Veterans Health Care System, San Antonio. 210-567-6691
    • Texas Diabetes Institute - University Health System, San Antonio. 210-567-6691

  26. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Run by Novo Nordisk A/S. Registry number NCT07607587.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    2 sites in Texas

    • Amarillo Medical Specialists, Amarillo
    • Elligo Clin Res Centre, Austin

  27. Prevention of Progression of Prediabetes, Obesity and CV Risk

    Phase 1. Run by The University of Texas Health Science Center at San Antonio. Registry number NCT06446531.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with prediabetes lower blood sugar and lose weight.

    Who can join. Adults 18+, have prediabetes, BMI 25+.

    1 site in Texas

    • University of Texas Health Science Center at San Antonio, San Antonio. 210-567-4900

  28. Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot

    Phase 1. Run by M.D. Anderson Cancer Center. Registry number NCT06759701.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with diabetes lower blood sugar.

    Who can join. Adults 18+, have diabetes, BMI 27+.

    1 site in Texas

    • The University of Texas M. D. Anderson Cancer Center, Houston. 713-792-3250

  29. Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

    Phase 1. Run by The Methodist Hospital Research Institute. Registry number NCT07651319.

    A study of a GLP-1 medicine, semaglutide, in people with Alzheimer's dementia (AD).

    Who can join. Adults 50 to 86, have Alzheimer's dementia (AD).

    1 site in Texas

  30. Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)

    Run by University of Texas at Austin. Registry number NCT07480109.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 30 to 60, women only, have obesity, BMI 25+.

    2 sites in Texas

  31. Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor

    Run by The University of Texas Health Science Center, Houston. Registry number NCT06654219.

    A study listed on ClinicalTrials.gov.

    1 site in Texas

    • The University of Texas Health Science Center at Houston, Houston. (713) 500-6202

  32. IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion

    Run by University of Texas Southwestern Medical Center. Registry number NCT07361874.

    A study of a GLP-1 medicine, semaglutide, in people with mild autonomous cortisol secretion (MACS).

    Who can join. Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+.

    1 site in Texas

    • University of Texas Southwestern Medical Center, Dallas. 2146456397

  33. Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

    Run by The University of Texas at Dallas. Registry number NCT07387796.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with substance use disorders.

    Who can join. Adults 18 to 70, have substance use disorders.

    1 site in Texas

  34. Tirzepatide Impact Assessment Study

    Run by Texas Tech University. Registry number NCT07740291.

    A study in people with obesity or overweight.

    Who can join. Adults 18+, have obesity or are overweight, BMI 27.5+.

    1 site in Texas

    • Nutrition Metabolic Health Initiative (NMHI), Lubbock. +18068342286

  35. The GLOW Study: GLP-1 and Lifestyle for Optimal Wellness

    Run by Saundra Jain. Registry number NCT07760896.

    A study listed on ClinicalTrials.gov.

    1 site in Texas

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.